Description - IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules.
Total raised: $155M
Investors 7
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.01.2021 | Series B | $155M | - |
Mentions in press and media 7
| Date | Title | Description | Source |
| 06.03.2024 | IO Biotech Announces Acceptance of Abstract to be Presented ... | - | globenewsw... |
| 07.08.2023 | IO Biotech, Inc. Announces $75 Million Private Placement Fin... | Offering includes participation from both new and existing healthcare-dedicated investors Proceeds e... | einpresswi... |
| 07.08.2023 | IO Biotech, Inc. Announces $75 Million Private Placement Fin... | - | globenewsw... |
| 11.05.2023 | IO Biotech Announces 2023 First-Quarter Results | The company expects to enroll 225 patients in its Phase 3 pivotal trial (IOB-013/KN-D18) in advanced... | einpresswi... |
| 13.01.2021 | IO Biotech : Completes Oversubscribed EUR 127 Million Series... | COPENHAGEN, Denmark, Jan. 13, 2021 /PRNewswire/ -- IO Biotech, a clinical-stage biopharmaceutical co... | marketscre... |
| 13.01.2021 | IO Biotech raises $155M to trial IDO and PD-L1 cancer vaccin... | IO Biotech has raised €127 million ($155 million) to fund clinical development of immune-modulating ... | fiercebiot... |
| 13.01.2021 | IO Biotech Completes €127M Series B Financing | IO Biotech, a Copenhagen, Denmark-based clinical-stage biopharmaceutical company developing novel, i... | finsmes.co... |